Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
To determine the Overall Response Rate (ORR), as defined as rate of complete response (CR) and partial response (PR) as per RECIST 1.1 in biological treatment-naïve patients with acral lentiginous melanoma treated with pembrolizumab
Epistemonikos ID: e161a919083b6d6260b449bb84e404ec41769d3d
First added on: Jun 14, 2024